Full metadata record
DC FieldValueLanguage
dc.contributor.authorPöhlmann, Johannes-
dc.contributor.authorMattli, Renato-
dc.contributor.authorSyleouni, Maria-Eleni-
dc.contributor.authorCarlander, Maria Johanna-
dc.contributor.authorMeier, Flurina-
dc.contributor.authorEgli, Philipp-
dc.contributor.authorGerber-Grote, Andreas-
dc.contributor.authorWieser, Simon-
dc.date.accessioned2021-03-11T15:40:52Z-
dc.date.available2021-03-11T15:40:52Z-
dc.date.issued2020-
dc.identifier.urihttps://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-bezeichnung-der-leistungen/re-evaluation-hta/scoping-berichte.htmlde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/21951-
dc.description.abstractAs patents for first-to-market biologics expire, subsequent-entry products – biosimilars – can become available. Biosimilars are not exact copies of their reference products but highly similar with regard to efficacy and safety and available at a discount. In Switzerland, relatively low biosimilar prescription rates have prompted interest in a health technology assessment (HTA) of the infliximab reference product relative to biosimilars for treating rheumatoid arthritis (RA). This scoping report determines the feasibility of such an HTA. We conducted a systematic literature search for evidence on efficacy, effectiveness, safety, and health economic outcomes of the infliximab reference product relative to biosimilars in RA. We also conducted a targeted search for evidence on biosimilar related ethical, legal, social, and organisational aspects. We identified 15 studies reporting on randomized controlled trials (RCTs), 14 real-world evidence (RWE) studies, and 11 health economic studies. RCTs reported a range of clinical efficacy, safety, pharmacokinetic/pharmacodynamic, immunogenicity, and patient-reported outcomes. RWE studies primarily reported on effectiveness, safety, and treatment discontinuation. Health economic studies were costing studies or budget impact analyses. A substantial body of literature was identified on biosimilar regulation in different settings. For legal and ethical aspects, we developed sets of questions that we considered important for discussing reference products and biosimilars, particularly with regard to non-medical switching. The evidence base suggested that an HTA comparing the infliximab reference product with its biosimilars for treatment of RA in infliximab-naïve and switched patients would be feasible. This HTA would have to include a systematic review (and possibly a meta-analysis) of efficacy, effectiveness, and safety as well as a budget impact analysis (but not necessarily a full economic evaluation).de_CH
dc.format.extent130de_CH
dc.language.isoende_CH
dc.publisherBundesamt für Gesundheitde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc616.7: Krankheiten des Bewegungsapparates und Orthopädiede_CH
dc.titleInfliximab reference product versus biosimilar for the treatment of rheumatoid arthritis : scoping reportde_CH
dc.typeWorking Paper – Gutachten – Studiede_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
zhaw.organisationalunitZentrum für Sozialrecht (ZSR)de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.